Hindustan Laboratories IPO: GMP, Pricing, Allotment Details, and 2026 Profit Forecast Unveiled!
Hindustan Laboratories, a pharmaceutical company focusing on generic formulations primarily for government institutions, is poised to announce its IPO details soon. The company has a significant presence in various therapeutic segments, with a diverse portfolio that has increased to 948 formulations as of September 2025. They cater to multiple states and union territories through a B2G model, indicating robust demand for their offerings. The IPO will consist of a fresh issue of 5 million shares and an offer for sale totaling 9.1 million shares, culminating in a total IPO size of 14.1 million shares. The company lists on both the NSE and BSE, targeting investments to bolster working capital and for general corporate purposes.
As for grey market sentiment, specific figures have yet to be disclosed, but anticipation surrounding the IPO suggests a potentially positive reception among investors. Given Hindustan Laboratories’ revenue growth trajectory—moving from INR 172.34 crores in FY 2023 to an expected INR 219.75 crores in FY 2025—there’s a compelling narrative for institutional and retail investors alike. Factors such as profitability margins and return on net worth (RONW) suggest that the company is positioned favorably within a competitive landscape, which may enhance investor confidence.
For Indian investors, the upcoming IPO represents an opportunity to engage with a company that is not only expanding its product offerings but is also strategically aligned with essential government contracts. With the pharmaceutical sector consistently demonstrating resilience, particularly in high-demand therapeutic categories, investor interest may be robust. However, potential investors should consider the overall market conditions, the performance of comparable peers, and the intrinsic financial health of Hindustan Laboratories before making investment decisions.
Source: The Economic Times
(Expert Note: This report was prepared by the Wealthova IPO team.)